People with Parkinson's disease who have a pacemaker-like device implanted in the brain spend an extra four-plus hours a day free of tremors and involuntary movements than they do on medication, ...

Parkinson’s disease is set to rise dramatically, with cases expected to more than double by 2050, largely due to an aging ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

Researchers have revealed neural circuits in the brainstem that are crucially involved in implementing decisions by ...